A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment
Authors
Keywords
Leucopenia, Anaemia, G-CSF, EPO, Filgrastim, Pegfilgrastim, Darbepoetin
Journal
Theoretical Biology and Medical Modelling
Volume 11, Issue 1, Pages 24
Publisher
Springer Nature
Online
2014-05-26
DOI
10.1186/1742-4682-11-24
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma
- (2013) S. Zeynalova et al. ANNALS OF HEMATOLOGY
- A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration
- (2013) Sibylle Schirm et al. PLoS One
- Does model-free forecasting really outperform the true model?
- (2013) F. Hartig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Model-free forecasting outperforms the correct mechanistic model for simulated and experimental data
- (2013) C. T. Perretti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans
- (2012) Markus Scholz et al. Theoretical Biology and Medical Modelling
- PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis
- (2011) M. Untch et al. ANNALS OF ONCOLOGY
- PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery
- (2011) M. Untch et al. ANNALS OF ONCOLOGY
- Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
- (2011) C. Zwick et al. ANNALS OF ONCOLOGY
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- A biomathematical model of human thrombopoiesis under chemotherapy
- (2010) Markus Scholz et al. JOURNAL OF THEORETICAL BIOLOGY
- Mathematical study of feedback control roles and relevance in stress erythropoiesis
- (2010) Fabien Crauste et al. JOURNAL OF THEORETICAL BIOLOGY
- Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats
- (2009) M. Scholz et al. CELL PROLIFERATION
- A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia
- (2009) M. Scholz et al. CELL PROLIFERATION
- The Impact of PEGylation on Biological Therapies
- (2008) Francesco M Veronese et al. BIODRUGS
- Mathematical model for G-CSF administration after chemotherapy
- (2008) Catherine Foley et al. JOURNAL OF THEORETICAL BIOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started